FDA approves $3.5 million treatment for hemophilia, now the most expensive drug in the world [CNN]
GoodRx Holdings, Inc. - Class A (GDRX)
Company Research
Source: CNN
Hemgenix is a gene therapy to treat adults with hemophilia B, a genetic bleeding disorder in which people do not produce a protein needed to create blood clots. About 1 in 40,000 people have the disease, most of whom are men. Typical treatment requires routine intravenous infusions to maintain sufficient levels of the missing or deficient clotting factor, but the new gene therapy is meant to be a one-time IV infusion. “Gene therapy for hemophilia has been on the horizon for more than two decades. Despite advancements in the treatment of hemophilia, the prevention and treatment of bleeding episodes can adversely impact individuals' quality of life,” Dr. Peter Marks, director of the FDA's Center for Biologics Evaluation and Research, said in a statement . “Today's approval provides a new treatment option for patients with Hemophilia B and represents important progress in the development of innovative therapies for those experiencing a high burden of disease associated with this for
Show less
Read more
Impact Snapshot
Event Time:
GDRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GDRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GDRX alerts
High impacting GoodRx Holdings, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
GDRX
News
- GDRX INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that GoodRx Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitBusiness Wire
- GDRX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that GoodRx Holdings, Inc. Investors Can Join the Class Action LawsuitAccesswire
- GDRX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that GoodRx Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!PR Newswire
- GDRX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that GoodRx Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!GlobeNewswire
- GDRX DEADLINE ALERT: Bernstein Liebhard LLP Reminds GoodRx Holdings, Inc. Investors of Upcoming Deadline Accesswire
GDRX
Earnings
- 2/29/24 - Beat
GDRX
Sec Filings
- 4/16/24 - Form 4
- 4/5/24 - Form S-3
- 3/19/24 - Form 4
- GDRX's page on the SEC website